Raymond James & Associates’s CRISPR Therapeutics CRSP Stock Holding History

Raymond James & Associates’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$1.5M	Sell	31,949 -6,484	-17%	-$329K	﹤0.01%	2424
2024 Q2	$2.08M	Buy	38,433 +3,479	+10%	+$201K	﹤0.01%	2152
2024 Q1	$2.38M	Buy	34,954 +3,115	+10%	+$223K	﹤0.01%	2055
2023 Q4	$1.99M	Buy	31,839 +3,231	+11%	+$179K	﹤0.01%	2100
2023 Q3	$1.3M	Sell	28,608 -159	-0.6%	-$8.21K	﹤0.01%	2288
2023 Q2	$1.61M	Sell	28,767 -28,365	-50%	-$1.61M	﹤0.01%	2190
2023 Q1	$2.58M	Buy	57,132 +13,729	+32%	+$667K	﹤0.01%	1880
2022 Q4	$1.76M	Buy	43,403 +6,176	+17%	+$328K	﹤0.01%	2074
2022 Q3	$2.43M	Buy	37,227 +3,972	+12%	+$288K	﹤0.01%	1849
2022 Q2	$2.02M	Sell	33,255 -18,335	-36%	-$1.08M	﹤0.01%	1974
2022 Q1	$3.24M	Sell	51,590 -8,467	-14%	-$532K	﹤0.01%	1812
2021 Q4	$4.55M	Sell	60,057 -27,729	-32%	-$2.42M	﹤0.01%	1620
2021 Q3	$9.83M	Buy	87,786 +8,479	+11%	+$1.06M	0.01%	1063
2021 Q2	$12.8M	Buy	79,307 +16,859	+27%	+$2.05M	0.01%	936
2021 Q1	$7.61M	Buy	62,448 +862	+1%	+$130K	0.01%	1184
2020 Q4	$9.43M	Buy	61,586 +2,492	+4%	+$295K	0.01%	990
2020 Q3	$4.94M	Buy	59,094 +3,828	+7%	+$340K	0.01%	1236
2020 Q2	$4.06M	Sell	55,266 -684	-1%	-$40K	0.01%	1316
2020 Q1	$2.37M	Buy	55,950 +5,322	+11%	+$275K	﹤0.01%	1471
2019 Q4	$3.08M	Sell	50,628 -4,646	-8%	-$254K	﹤0.01%	1561
2019 Q3	$2.27M	Buy	55,274 +2,244	+4%	+$107K	﹤0.01%	1702
2019 Q2	$2.5M	Buy	53,030 +1,433	+3%	+$57.3K	﹤0.01%	1663
2019 Q1	$1.84M	Buy	51,597 +3,040	+6%	+$105K	﹤0.01%	1816
2018 Q4	$1.39M	Buy	48,557 +5,227	+12%	+$182K	﹤0.01%	1874
2018 Q3	$1.92M	Sell	43,330 -38,476	-47%	-$2.02M	﹤0.01%	1833
2018 Q2	$4.81M	Sell	81,806 -525	-0.6%	-$29.9K	0.01%	1207
2018 Q1	$3.76M	Sell	82,331 -507	-0.6%	-$20.9K	0.01%	1311
2017 Q4	$1.95M	Buy	82,838 +34,178	+70%	+$649K	﹤0.01%	1710
2017 Q3	$870K	Buy	48,660 +28,651	+143%	+$520K	﹤0.01%	2177
2017 Q2	$321K	Buy	+20,009	New	+$331K	﹤0.01%	2678

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Raymond James & Associates's CRSP Position: Q3 2024 in Review

Raymond James & Associates reduced its CRISPR Therapeutics (CRSP) stake by 17% in Q3 2024, selling an estimated $329K and leaving 31,949 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2424.

Raymond James & Associates first reported a position in CRSP in Q2 2017 and has held it in 30 quarters since. The position peaked at $12.8M in Q2 2021. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

Raymond James & Associates held 31,949 shares of CRISPR Therapeutics worth $1.5M as of Q3 2024.
Raymond James & Associates sold 6,484 CRISPR Therapeutics shares in Q3 2024, an estimated $329K.
CRISPR Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2424 holding.
Raymond James & Associates first reported a position in CRISPR Therapeutics in Q2 2017 and has held it in 30 quarters since.
Raymond James & Associates's CRISPR Therapeutics position peaked at $12.8M in Q2 2021.
416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.